Diroximel fumarate DR is a Small Molecule owned by Biogen, and is involved in 18 clinical trials, of which 13 were completed, 3 are ongoing, and 2 are planned.

Diroximel fumarate (ALKS-8700) acts as NRF2 decoy, selectively binds to KEAP1. Inhibition of KEAP1 leads to the activation of NFE2-related factor 2 (NRF2). Modification of C151 in KEAP1 and NRF2 drives expression of a battery of genes via its interaction with the antioxidant response element (ARE). Activated NRF2 directed transcription improves redox balance, alleviates mitochondrial dysfunction, increases mitochondrial biogenesis, enhances autophagy, and reduces inflammation. Neuronal degeneration which is implicated in multiple sclerosis is linked to oxidative stress. MMF prevents oxidative stress that improves neuronal function.

The revenue for Diroximel fumarate DR is expected to reach a total of $12.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Diroximel fumarate DR NPV Report.

Diroximel fumarate DR is currently owned by Biogen.

Diroximel fumarate DR Overview

Diroximel fumarate (vumerity) is an anti-neoplastic agent. It is formulated as hard gelatin delayed release (gastro resistant) capsules for oral route of administration. Vumerity is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Diroximel fumarate (vumerity) is also under development for the treatment of relapsing-remitting multiple sclerosis. It is administered through oral route as capsule. The drug candidate acts by targeting the mutated kelch like ECH associated protein 1 (KEAP1).

Biogen Overview

Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$10,981.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.3% over FY2020. In FY2021, the company’s operating margin was 25.9%, compared to an operating margin of 33.8% in FY2020. In FY2021, the company recorded a net margin of 14.2%, compared to a net margin of 29.8% in FY2020. The company reported revenues of US$2,508.5 million for the third quarter ended September 2022, a decrease of 3.1% over the previous quarter.

Quick View – Diroximel fumarate DR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Diroximel fumarate DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.